middle.news
Radiopharm Theranostics Hits 50% Enrollment in RAD101 Brain Metastases Trial
8:40am on Monday 17th of November, 2025 AEDT
•
Healthcare
Read Story
Radiopharm Theranostics Hits 50% Enrollment in RAD101 Brain Metastases Trial
8:40am on Monday 17th of November, 2025 AEDT
Key Points
50% patient enrollment achieved in Phase 2b RAD101 trial
Early data show significant tumor uptake compared to MRI
RAD101 targets fatty acid synthase overexpressed in brain metastases
Trial topline results expected in first half of 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE